Benjamin J. Zeskind, the PRESIDENT AND CEO of $IMRX, bought 21,000 shares of the company on 06-18-2025 for an estimated $50,143. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their holdings of this class of stock by approximately 0.9%. Following this trade, they now own 2,302,852 shares of this class of $IMRX stock.
$IMRX Insider Trading Activity
$IMRX insiders have traded $IMRX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:
- THOMAS J. SCHALL purchased 40,485 shares for an estimated $89,277
- BENJAMIN J. ZESKIND (PRESIDENT AND CEO) purchased 21,000 shares for an estimated $50,143
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IMRX Hedge Fund Activity
We have seen 14 institutional investors add shares of $IMRX stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MARSHALL WACE, LLP added 786,537 shares (+3669.9%) to their portfolio in Q1 2025, for an estimated $1,195,536
- PROSIGHT MANAGEMENT, LP removed 190,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $418,000
- ROCKEFELLER CAPITAL MANAGEMENT L.P. removed 177,377 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $269,613
- PRICE T ROWE ASSOCIATES INC /MD/ removed 108,115 shares (-14.1%) from their portfolio in Q1 2025, for an estimated $164,334
- MILLENNIUM MANAGEMENT LLC removed 79,871 shares (-77.6%) from their portfolio in Q1 2025, for an estimated $121,403
- TD ASSET MANAGEMENT INC removed 79,810 shares (-52.9%) from their portfolio in Q1 2025, for an estimated $121,311
- CORIENT PRIVATE WEALTH LLC removed 63,740 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $96,884
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IMRX Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 05/07/2025
To track analyst ratings and price targets for $IMRX, check out Quiver Quantitative's $IMRX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
